MONROVIA CA / ACCESSWIRE / June 9, 2016 / Cantech Holding, Inc. f/k/a Reve Technologies, Inc. (OTCPK: BSSP) (the “Company” or “Cantech”) a development stage immunotherapeutic based technology company today announced a Letter to Shareholders updating current activities and outlining its corporate strategy for 2016, which will also become available and posted on its website at www.cantechholding.com.
Preface: As previously reported the Company is proud to launch our new corporate identity as Cantech, which we believe clearly reflects our business strategy. The name represents the fusion of our innovative approach regarding our commitment to improving lives by helping to bring impactful immunotherapeutic treatment(s) to market initially in Mexico for cancer indication.
Dear Shareholders,
Cantech Holding, Inc., (formerly Reve Technologies, Inc.) recently acquired the exclusive sub licensing agreement and all associated operations including the import export license in Mexico and the efforts to obtain Permits through a Mexican based group located in Southern California, with strategic alliances in both Tijuana and Mexico City from the related Delaware Corporation, Cantech Pharma, Inc., a separate entity which holds Master Licenses via its Trust ownership and patent holders. With this acquisition the Company has begun the integration of Administration of the two entities as the business strategy has transitioned to an Immunotherapy based plan. The construction of the Web page located at www.cantechholding.com is a priority and continues in development and fine tuning daily.
The Administrative staff of both entities is minimal as the activity of one REVE (now Cantech Holding, Inc.) which initiated earlier in April 2016 focused on acquiring an operation for both the entity and Cantech Holding management along with principals of Cantech Pharma, Inc. are focused on developing the Market in Mexico. While Management wishes it had the resources and manpower to fix all the Administrative issues at once, reality and the efficient use of manpower and monetary resources dictate that Management focus on bringing the reports current and allocating whatever spare manpower and cash available to issues such as the Web Page completion. Management’s priority has been those issues such as the name change, completion of the acquisition, current 8-k filings and resolution of the issues hindering the filing of the delinquent year end 10-K and the first quarter 10-Q. These reports will represent the operations prior to the acquisition of the Immunotherapy license with detail disclosure in the Subsequent event footnote in the financial statements. This footnote, when filed, will include all the information regarding the acquired assets. Any material change in any information previously disclosed to the market will be the subject of future press release and immediately released to the investing public as required by the regulatory agencies. If a material event occurs that changes or positively or negatively impacts the process of obtaining the permits then the Company would immediately make those facts known. If there is no change and the process is continuing as expect other than a delay then the Company will remain silent, patiently waiting on the Government Agency in Mexico to complete its permitting process. With little spare resources telling the Market that there is no change in the expectations of receiving the permit other than it taken longer than expected would in management’s judgment not be a good use of funds unless warranted. If the Company hasn’t disclosed they have been awarded the permit or that the permit will not be issued then the ordinary man assumption would be that the Agency is taking longer than expected.
The Company has completed the acquisition of the Assets of Cantech Pharma specific to the Mexican operations. This was not a merger but an asset acquisition. The Company reported the closing of the acquisition.
We’ve also are working on our short and long term plans to strengthen our financial footing, with our goals to raise 2.5 to 5 million as soon as practicable to be available for development, manufacture and commercialization, expansion to other potential markets, and working capital for proposed growth. To that end we are meeting with short and long term accredited and institutional investors with no assurance or guarantee we will be successful in our attempts.
The Company’s Current Management is focused on maintaining both Shareholder Value and honoring the Company investor related obligations entered into in prior years. The Cantech Holding Management Team also represents the sellers of the Immunotherapy Assets who are now the largest non-dilutable shareholders of the Company and which aligns their interest with those of the other shareholders. No announcements of a reverse split have been made and if the Board had made that decision a press release and an 8-K would have been warranted. Having said that any future decision, if there ever is one will be announced immediately to the investing public.
Addressing the conversion of aged debt since the announcing of the transaction it is important to realize that all the convertible debt being monetized at this time we believe has been on the Balance Sheet of the books for over a year or longer. The sale of convertible debt must meet the applicable conditions set forth in Rule 144 of the Security and Exchange Commission. Management is honoring these obligations under the terms of existing agreement which is resulting in shares coming into the market as was disclosed in the Company filings prior to the delinquent periods but again must first meet the conditions of Rule 144 or other applicable exemption as or if available to sellers. This issue specifically was reviewed by the Master License Holders Cantech Pharma, Inc. management and Trust (sellers) prior to the transaction. REVE Management was fully transparent in answering the questions as all the information was included in its public filings. The Sellers believed that these shares would come into the market based on this public information and negotiated with the buyers for a non-dilutable position related to the common shares which was also disclosed in the public filings. The Sellers believed that their assets had a certain value and the REVE entity had an inherent value even with its delinquent issues and overhang from convertible debt. There have been to date no shares sold by Cantech Holding Inc., there has only been honoring of existing debt instrument conversions.
The previous management of REVE gave up the majority of the super majority voting preferred shares, effectively selling control to the Sellers to obtain the opportunity to acquire the Immunotherapy Licensing Agreement along with the Mexican Operations. Their commitment to building shareholder value is evident by the strategic switch to an Immunotherapy based business plan. The result was a stock going from being illiquid with zero to little volume at .0001 to a stock that trades recently over $20k a day on average even with the shares coming into the market from the conversions. The Company has also positioned itself to be part of the highly visible Immunotherapy Cancer Treatment Industry one of the fastest growing segments of the Pharmaceutical industry with an overall 50B market potential noting if our market share would even be a capture rate of .001% that would amount to an initial $50,000,000 annual revenue potential. While the price of the shares traded have ranged from .0001 to .0009 over the last seven weeks based on speculation by investors the Company management remains confident in its treatment and the future results of the sale of its product in the licensed territory of Mexico. With Immunotherapy Cancer Treatment Industry and related technology still in its infancy, and just as the Internet has become a driver of global commerce in record time, we believe the potential for being in position for explosive growth is nearly upon us.
We hope you feel this has addressed the initial concerns and or interests through comments shareholders have raised and you have come away with a better understanding of the public information and potential of the Company.
On behalf of our management team, we wish to personally thank you for your continued support.
Sincerely,
Cantech Holding Management
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can’t recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating
super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent – fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company’s Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico.
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Reve Technologies, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Reve Technologies, Inc.’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Reve Technologies, Inc.’s filings with the Securities and Exchange Commission.
Public Relations and Shareholder
Information
Name: Dennis Alexander
Phone: (602) 326-7371
Email: revestechnology1@gmail.com
SOURCE: Cantech Holding, Inc.
ReleaseID: 440964
